EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening Campaign and Docking Investigations in Identifying New Hit Compounds as Inhibitors of Human Carbonic Anhydrases Expressed In Tumour Cells

Federico Ricci, Andrea Angeli, Francesca Mancuso, Laura De Luca, Claudiu T Supuran iD, Rosaria Gitto iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Federico Ricci und 5 weiteren Autor:innen. Beteiligte Einrichtung: CHIBIOFARAM Department, University of Messina, Viale F. d'Alcontres 31, 98166, Messina, Italy. Hauptthemen laut MEDLINE: Carbonic Anhydrases, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor‐expressed human carbonic anhydrase (hCA) isoforms hCA IX and hCA XII have been extensively studied to develop anticancer agents targeting solid tumors in combined therapy. These CA isoforms are considered key factors in controlling tumor microenvironment (TME) of cancer lines that develop high metastatic activity. Herein, we report the discovery of potent hCA IX/hCA XII inhibitors that were disclosed through a screening campaign on an in‐house collection of arylsulfonamides preliminary tested toward other hCAs. Among them, the N ‐(4‐sulfamoylphenyl)naphthalene‐2‐carboxamide ( 12 ) and N ‐(4‐sulfamoylphenyl)‐3,4‐dihydroisoquinoline‐2(1 H )‐carbothioamide ( 15 ) proved to be the most intriguing hCA IX/hCA XII inhibitors displaying favourable selectivity ratios over widespread hCA I and hCA II isoforms. To explore their binding mode, we conducted docking studies that described the poses of the best inhibitors in the catalytic site of hCA IX and hCA XII, thus suggesting the privileged pattern of interactions. These structural findings might further improve the knowledge for a successful identification of new sulfonamides as adjuvant agents in cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic AnhydrasesNeoplasmsHumansStructure-Activity RelationshipCarbonic Anhydrase IXAntigens, NeoplasmCarbonic Anhydrase IProtein IsoformsCarbonic Anhydrase InhibitorsMolecular StructureTumor Microenvironment

Stichwörter der Autor:innen

antitumor agentsarylsulfonamidescarbonic anhydrasedocking studiesmolecular modeling

Substanzen

Carbonic AnhydrasesCarbonic Anhydrase IXAntigens, NeoplasmCarbonic Anhydrase IProtein IsoformsCarbonic Anhydrase Inhibitors

Autor:innen und Institutionen

  • CHIBIOFARAM Department, University of Messina, Viale F. d'Alcontres 31, 98166, Messina, Italy.
  • NEUROFARBA Department, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy.

ORCID-Profile: Claudiu T Supuran, Rosaria Gitto

Zitieren

APA

Ricci, F., Angeli, A., Mancuso, F., De Luca, L., Supuran, C. T., & Gitto, R. (2023). Screening Campaign and Docking Investigations in Identifying New Hit Compounds as Inhibitors of Human Carbonic Anhydrases Expressed In Tumour Cells. ChemMedChem. https://doi.org/10.1002/cmdc.202300330

Vancouver

Ricci F, Angeli A, Mancuso F, De Luca L, Supuran CT, Gitto R. Screening Campaign and Docking Investigations in Identifying New Hit Compounds as Inhibitors of Human Carbonic Anhydrases Expressed In Tumour Cells. ChemMedChem. 2023. doi:10.1002/cmdc.202300330

BibTeX
@article{Ricci2023,
  author = {Ricci, Federico and Angeli, Andrea and Mancuso, Francesca and De Luca, Laura and Supuran, Claudiu T and Gitto, Rosaria},
  title = {Screening Campaign and Docking Investigations in Identifying New Hit Compounds as Inhibitors of Human Carbonic Anhydrases Expressed In Tumour Cells},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300330}
}
Kostenlos starten →